Loading data for IMMX — first visit, this takes a few seconds.

Alert

Immix Biopharma Inc. (IMMX)

NasdaqCM: IMMX · Real-Time Price · USD

13.66

+0.50 (3.80%)

At close: Aug 21, 2026, 8:00 PM

13.60

-0.44%

After-hours: 7:30 PM

The price, the headline numbers and the latest news, in one place.

3.80% (1D)

No data available

Bid	9.9
Market Cap	972.45M
Revenue (ttm)	n/a
Net Income (ttm)	-39.92M
	0.11
	-0.88
	n/a
	-15.11
P/B (ttm)	4.27
P/S (ttm)	n/a
Earnings Date	n/a

Ask	16.84
Volume	1,510,009
Avg. Volume (20D)	1,827,153
Open	13.37
Previous Close	13.16
Day's Range	13.12 - 13.76
52-Week Range	1.94 - 13.76
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About IMMX

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California....

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 16, 2021

Employees 21

Stock Exchange NasdaqCM

Ticker Symbol IMMX

Website https://www.immixbio.com

Full Company Profile

Financial Performance

In 2025, Immix Biopharma's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -29.44M, an increase of 36.21%.

Financial Statements

Earnings Surprise

Immix Biopharma has released their quarterly earnings on Aug 7, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -0.18 misses estimates by 0.00, with 18.18% YoY growth.

News

1 month ago · Investor's Business Daily

Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run

One of Rhode Island's most-wanted fugitives was captured Monday after apparently hiding out for 20 years as a biotech executive.

2 months ago · Zacks

Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet

The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

2 months ago · Simply Wall St.

Exploring 3 High Growth Tech Stocks in the US Market

Over the last 7 days, the United States market has dropped 2.7%, yet it remains up by 23% over the past year, with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying...

3 months ago · Zacks

Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?

The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

3 months ago · Simply Wall St.

3 Growth Companies With High Insider Ownership Expect Earnings Growth Up To 63%

Over the last 7 days, the United States market has risen by 1.5%, contributing to a remarkable 26% climb over the past year, with earnings forecasted to grow by 17% annually. In this flourishing envir...

Page 1 of 2

Immix Biopharma Inc. (IMMX)